Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 2/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179442 | 1.00 | ITGB3 (0.43) | ITGB3ITGA2BRXRANR1H2NR1H3 | |
| SCHEMBL4185656 | 0.89 | SLC7A5 (0.47) | PLA2G2AHDAC1HDAC6MMP1MMP3 | |
| SCHEMBL15908890 | 0.88 | PLA2G2A (0.43) | ITGB3ITGA2BPLA2G2AHDAC1HDAC6 | |
| SCHEMBL4187842 | 0.88 | KMT2A (0.44) | ITGB3ITGA2BPLA2G2AMMP1MMP3 | |
| SCHEMBL4179492 | 0.88 | KMT2A (0.44) | ITGB3ITGA2BPLA2G2AMMP1MMP3 | |
| SCHEMBL557681 | 0.87 | HDAC1 (0.44) | ITGB3ITGA2BRXRANR1H2NR1H3 | |
| SCHEMBL557604 | 0.85 | HDAC1 (0.42) | PLA2G2AHDAC1HDAC6HDAC2 | |
| SCHEMBL26091793 | 0.83 | ITGB3 (0.46) | ITGB3ITGA2BHDAC1HDAC6HDAC2 | |
| SCHEMBL26091795 | 0.83 | ITGB3 (0.46) | ITGB3ITGA2BHDAC1HDAC6HDAC2 | |
| SCHEMBL26091800 | 0.83 | ITGB3 (0.46) | ITGB3ITGA2BHDAC1HDAC6HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024390-B1 | INSULIN DERIVATIVE | NOVO NORDISK AS (DK) | 2015-08-19 | — | — | EP | disclosed |
| US-8796205-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2014-08-05 | — | — | US | disclosed |
| US-20090105121-A1 | Insulin Derivative | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-2024390-A1 | INSULIN DERIVATIVE | Novo Nordisk A/S (DK) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007128815-A1 | INSULIN DERIVATIVE | NOVO NORDISK A/S (DK) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105121-A1 | Insulin Derivative | INSR, IAPP, GPR119 | ITGB3 3539/4885ITGA2B 3265/4885RXRA 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.